Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes
| Autor: | Libin Xia, Jingzhu Cao, Ming Ji, Dajin Zou |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty endocrine system diseases Sitagliptin/metformin Insulin Glargine 030209 endocrinology & metabolism Type 2 diabetes Gastroenterology Body Mass Index Sitagliptin Phosphate 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Hypoglycemic Agents Obesity 030212 general & internal medicine Aged Glycemic Glycated Hemoglobin business.industry Insulin glargine nutritional and metabolic diseases Clinical Trial/Experimental Study General Medicine Middle Aged medicine.disease Metformin Treatment Outcome Postprandial Endocrinology Diabetes Mellitus Type 2 Sitagliptin Drug Therapy Combination Female Drug Monitoring business Research Article medicine.drug |
| Zdroj: | Medicine |
| ISSN: | 0025-7974 |
| DOI: | 10.1097/md.0000000000002961 |
| Popis: | To compare the therapeutic effects of different regimens in Chinese obese type 2 diabetic mellitus (T2DM) patients. From October 2013 to July 2014, a total of 166 T2DM outpatients who attended the Shanghai Changhai Hospital and the Yijishan Hospital of Wannan Medical College were randomly assigned into an experimental sitagliptin/metformin combined with low caloric diet group (n = 115) and an insulin glargine combined with metformin control group (n = 51). Inclusion criteria were body mass index (BMI) ≥ 25 kg/m2 and diagnosed with T2DM with glycosylated hemoglobin (glycated hemoglobin A1C [HbA1c]) >9%. Main outcome parameters were fasting plasma glucose, postprandial plasma glucose, BMI, HbA1c, fasting C-peptide, 2-h postprandial C-peptide, triglyceride (TG), total cholesterol (TC), high-density cholesterol (HDL-C), and low-density cholesterol (LDL-C), which were determined by the 75 g steamed-bun meal tolerance test before and 4, 8, 12, and 24 weeks after the treatment started. Treatment costs and life quality were also assessed. BMI, HbA1C, TG, TC, and LDL were significantly more reduced (P 9%, oral sitagliptin/metformin combined with a low caloric diet effectively and economically maintained glycemic control and significantly improved life quality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|